The drugmaker said access to the treatment would be extremely limited at first, with only enough doses for 50,000 patients. Here’s the latest.
Source: New York Times
The drugmaker said access to the treatment would be extremely limited at first, with only enough doses for 50,000 patients. Here’s the latest.
Source: New York Times